Ignite Creation Date:
2025-12-25 @ 12:05 AM
Ignite Modification Date:
2025-12-25 @ 10:04 PM
Study NCT ID:
NCT00171158
Status:
COMPLETED
Last Update Posted:
2021-06-25
First Post:
2005-09-12
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
1999-07-26
Start Date Type:
ACTUAL
Primary Completion Date:
2013-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-04-22
Completion Date Type:
ACTUAL
First Submit Date:
2005-09-12
First Submit QC Date:
None
Study First Post Date:
2005-09-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-05-07
Results First Submit QC Date:
None
Results First Post Date:
2021-06-25
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-06-03
Last Update Post Date:
2021-06-25
Last Update Post Date Type:
ACTUAL